Shah Vishank, Lazaridis Christos
Department of Neurology, Division of Neurocritical Care and Vascular Neurology Baylor College of Medicine, Houston, TX.
Department of Neurology, Division of Neurocritical Care and Vascular Neurology Baylor College of Medicine, Houston, TX.
J Crit Care. 2015 Aug;30(4):784-6. doi: 10.1016/j.jcrc.2015.03.028. Epub 2015 Apr 8.
Extracorporeal membrane oxygenation (ECMO) is used to resuscitate patients with cardiovascular collapse or refractory respiratory failure. Determination of death by neurologic criteria requires the performance of an apnea test. Few data exist describing performance of an apnea test in this setting. Understanding of ECMO physiology and mechanics is critical in the efficient and proper delivery of apnea testing.
We report the case of a young woman on venovenous ECMO post-cardiac arrest in whom we performed an apnea test to determine death by neurologic criteria. Decreasing sweep gas flow rate to 0 L/min led to a Paco2 increase of 3 to 5 mm Hg/min of apnea. Stable oxygen saturation was maintained with supplemental oxygen via the endotracheal tube. We further review all reported to date cases of apnea testing in the setting of ECMO.
A total of 8 adult and 3 pediatric cases have been reported in the literature. Decreasing sweep rate is necessary to achieve hypercapnia. Oxygenation is maintained through oxygen circuit delivery with or without supplemental diffusion oxygenation via the endotracheal tube. Hemodynamics can be managed with circuit pump flow in addition to vasoactive medication support. Continuous positive airway pressure is recommended during the test.
According to current guidelines, apnea testing has to be performed after prerequisites have been met and in a fashion where hypercapnia is achieved in the face of stable oxygenation and hemodynamics. Performance of the test during ECMO is feasible.
体外膜肺氧合(ECMO)用于抢救心血管功能衰竭或难治性呼吸衰竭患者。通过神经学标准判定死亡需要进行一项呼吸暂停试验。在这种情况下,描述呼吸暂停试验执行情况的数据很少。了解ECMO的生理学和力学原理对于高效且恰当地进行呼吸暂停试验至关重要。
我们报告了一名年轻女性在心脏骤停后接受静脉-静脉ECMO治疗的病例,我们对其进行了呼吸暂停试验以通过神经学标准判定死亡。将扫气流量速率降至0升/分钟导致呼吸暂停期间动脉血二氧化碳分压(Paco2)以每分钟3至5毫米汞柱的速度升高。通过气管内导管补充氧气维持了稳定的血氧饱和度。我们进一步回顾了迄今为止所有报道的在ECMO情况下进行呼吸暂停试验的病例。
文献中总共报道了8例成人病例和3例儿科病例。降低扫气速率对于实现高碳酸血症是必要的。通过氧气回路输送维持氧合,无论是否通过气管内导管进行补充性弥散氧合。除血管活性药物支持外,可通过回路泵流量管理血流动力学。建议在试验期间使用持续气道正压通气。
根据当前指南,呼吸暂停试验必须在满足前提条件后进行,并且要以在稳定的氧合和血流动力学情况下实现高碳酸血症的方式进行。在ECMO期间进行该试验是可行的。